vs
Side-by-side financial comparison of BCB BANCORP INC (BCBP) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
BCB BANCORP INC is the larger business by last-quarter revenue ($26.2M vs $23.0M, roughly 1.1× Intellia Therapeutics, Inc.). BCB BANCORP INC runs the higher net margin — -49.7% vs -416.2%, a 366.5% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 13.1%). BCB BANCORP INC produced more free cash flow last quarter ($34.9M vs $-69.4M). Over the past eight quarters, BCB BANCORP INC's revenue compounded faster (1.8% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
BCBP vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.2M | $23.0M |
| Net Profit | $-12.0M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | -71.9% | -428.9% |
| Net Margin | -49.7% | -416.2% |
| Revenue YoY | 13.1% | 78.8% |
| Net Profit YoY | -467.6% | 25.7% |
| EPS (diluted) | $-0.73 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.2M | $23.0M | ||
| Q3 25 | $26.5M | $13.8M | ||
| Q2 25 | $25.2M | $14.2M | ||
| Q1 25 | $23.8M | $16.6M | ||
| Q4 24 | $23.1M | $12.9M | ||
| Q3 24 | $26.2M | $9.1M | ||
| Q2 24 | $20.4M | $7.0M | ||
| Q1 24 | $25.3M | $28.9M |
| Q4 25 | $-12.0M | $-95.8M | ||
| Q3 25 | $4.3M | $-101.3M | ||
| Q2 25 | $3.6M | $-101.3M | ||
| Q1 25 | $-8.3M | $-114.3M | ||
| Q4 24 | $3.3M | $-128.9M | ||
| Q3 24 | $6.7M | $-135.7M | ||
| Q2 24 | $2.8M | $-147.0M | ||
| Q1 24 | $5.9M | $-107.4M |
| Q4 25 | -71.9% | -428.9% | ||
| Q3 25 | 21.9% | -808.9% | ||
| Q2 25 | 19.9% | -772.2% | ||
| Q1 25 | -49.2% | -726.6% | ||
| Q4 24 | 19.9% | -1059.9% | ||
| Q3 24 | 35.7% | -1589.0% | ||
| Q2 24 | 19.5% | -1998.6% | ||
| Q1 24 | 33.0% | -394.0% |
| Q4 25 | -49.7% | -416.2% | ||
| Q3 25 | 16.1% | -735.2% | ||
| Q2 25 | 14.2% | -710.8% | ||
| Q1 25 | -35.0% | -687.6% | ||
| Q4 24 | 14.1% | -1001.2% | ||
| Q3 24 | 25.5% | -1489.5% | ||
| Q2 24 | 13.8% | -2112.6% | ||
| Q1 24 | 23.2% | -371.3% |
| Q4 25 | $-0.73 | $-0.81 | ||
| Q3 25 | $0.22 | $-0.92 | ||
| Q2 25 | $0.18 | $-0.98 | ||
| Q1 25 | $-0.51 | $-1.10 | ||
| Q4 24 | $0.17 | $-1.27 | ||
| Q3 24 | $0.36 | $-1.34 | ||
| Q2 24 | $0.14 | $-1.52 | ||
| Q1 24 | $0.32 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.3M | $671.4M |
| Total Assets | $3.3B | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $449.9M | ||
| Q3 25 | — | $511.0M | ||
| Q2 25 | — | $459.7M | ||
| Q1 25 | — | $503.7M | ||
| Q4 24 | — | $601.5M | ||
| Q3 24 | — | $658.1M | ||
| Q2 24 | — | $691.1M | ||
| Q1 24 | — | $791.3M |
| Q4 25 | $304.3M | $671.4M | ||
| Q3 25 | $318.5M | $748.4M | ||
| Q2 25 | $315.7M | $715.3M | ||
| Q1 25 | $314.7M | $779.9M | ||
| Q4 24 | $323.9M | $872.0M | ||
| Q3 24 | $328.1M | $962.6M | ||
| Q2 24 | $320.7M | $971.1M | ||
| Q1 24 | $320.1M | $1.0B |
| Q4 25 | $3.3B | $842.1M | ||
| Q3 25 | $3.4B | $925.3M | ||
| Q2 25 | $3.4B | $898.9M | ||
| Q1 25 | $3.5B | $986.2M | ||
| Q4 24 | $3.6B | $1.2B | ||
| Q3 24 | $3.6B | $1.2B | ||
| Q2 24 | $3.8B | $1.2B | ||
| Q1 24 | $3.8B | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $-69.3M |
| Free Cash FlowOCF − Capex | $34.9M | $-69.4M |
| FCF MarginFCF / Revenue | 133.3% | -301.6% |
| Capex IntensityCapex / Revenue | 4.0% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $58.2M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | $-69.3M | ||
| Q3 25 | $8.7M | $-76.9M | ||
| Q2 25 | $10.3M | $-99.6M | ||
| Q1 25 | $5.0M | $-148.9M | ||
| Q4 24 | $67.7M | $-85.2M | ||
| Q3 24 | $43.5M | $-84.8M | ||
| Q2 24 | $8.1M | $-58.2M | ||
| Q1 24 | $8.3M | $-120.7M |
| Q4 25 | $34.9M | $-69.4M | ||
| Q3 25 | $8.5M | $-76.9M | ||
| Q2 25 | $10.2M | $-99.9M | ||
| Q1 25 | $4.7M | $-149.7M | ||
| Q4 24 | $66.5M | $-86.2M | ||
| Q3 24 | $43.4M | $-86.1M | ||
| Q2 24 | $8.1M | $-59.2M | ||
| Q1 24 | $8.1M | $-123.2M |
| Q4 25 | 133.3% | -301.6% | ||
| Q3 25 | 32.0% | -558.2% | ||
| Q2 25 | 40.4% | -701.0% | ||
| Q1 25 | 19.8% | -900.1% | ||
| Q4 24 | 287.5% | -669.4% | ||
| Q3 24 | 166.0% | -945.2% | ||
| Q2 24 | 39.6% | -850.9% | ||
| Q1 24 | 32.3% | -425.7% |
| Q4 25 | 4.0% | 0.5% | ||
| Q3 25 | 1.1% | 0.2% | ||
| Q2 25 | 0.6% | 1.7% | ||
| Q1 25 | 1.2% | 4.4% | ||
| Q4 24 | 5.3% | 7.6% | ||
| Q3 24 | 0.3% | 14.0% | ||
| Q2 24 | 0.2% | 14.5% | ||
| Q1 24 | 0.6% | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.70× | — | ||
| Q3 24 | 6.53× | — | ||
| Q2 24 | 2.88× | — | ||
| Q1 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCBP
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
